XML 65 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated statements of cash flows - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
 [1]
Cash flows from (used in) operating activities [abstract]        
Net income attributable to equity holders of Sanofi € 5,560 € 5,400 [1] € 8,371 [1]  
Net income excluding the exchanged/held-for-exchange Animal Health business [1] (64) (338) (401)  
Net income attributable to non-controlling interests 58 36 [1],[2] 113 [1],[2]  
Share of undistributed earnings from investments accounted for using the equity method 82 293 [1] (45) [1]  
Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets 3,586 4,429 [1] 3,108 [1]  
Gains and losses on disposals of non-current assets, net of tax [3] (366) (364) [1] (590) [1]  
Net change in deferred taxes (802) (1,233) [1] (529) [1]  
Net change in non-current provisions and other non-current liabilities [4] 812 105 [1] 48 [1]  
Cost of employee benefits (share-based payments) 278 260 [1] 234 [1]  
Impact of the workdown of acquired inventories remeasured at fair value 10 9 [1] 3 [1]  
Other profit or loss items with no cash effect on cash flows generated by operating activities [5] 68 261 [1] 120 [1]  
Operating cash flow before changes in working capital from continuing operations 9,222 8,858 [1] 10,432 [1]  
Adjustments to reconcile profit (loss) [abstract]        
(Increase)/decrease in inventories (477) (866) [1] (918) [1]  
(Increase)/decrease in accounts receivable (28) (472) [1] (500) [1]  
Increase/(decrease) in accounts payable 789 258 [1] 340 [1]  
Net change in other current assets and other current liabilities (899) 1,493 [1] 284 [1]  
Cash flows from (used in) operating activities, continuing operations [6] 8,607 9,271 [1] 9,638 [1]  
Net cash provided by/(used in) operating activities [6] 9,081 10,258 [1] 10,526 [1]  
Cash flows from (used in) operating activities, discontinued operations 474 987 [1] 888 [1]  
Cash flows from (used in) investing activities [abstract]        
Net cash provided by/(used in) operating activities from the discontinued Opella business (3,195) (2,906) [1] (2,103) [1]  
Acquisitions of consolidated undertakings and investments accounted for using the equity method [7] (1,901) (2,535) [1] (987) [1]  
Acquisitions of other equity investments (623) (134) [1] (487) [1]  
Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets, net of tax [8] 1,461 807 [1] 1,340 [1]  
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax [9] 0 42 [1] 134 [1]  
Net change in other non-current assets (40) (224) [1] (14) [1]  
Cash flows from (used in) investing activities, continuing operations (4,298) (4,950) [1] (2,117) [1]  
Net cash provided by/(used in) continuing investing activities (4,407) (6,200) [1] (2,075) [1]  
Cash flows from (used in) investing activities, discontinued operations [10] (109) (1,250) [1] 42 [1]  
Cash flows from (used in) financing activities [abstract]        
Net cash provided by/(used in) investing activities of the discontinued Opella business(i) 187 195 [1] 188 [1]  
Dividends paid:        
to shareholders of Sanofi (4,704) (4,454) [1] (4,168) [1]  
to non-controlling interests, excluding BMS (38) (56) [1] (97) [1]  
Payments received/(made) on changes of ownership interest in a subsidiary without loss of control 0 (3) [1] 0 [1]  
Additional long-term debt contracted 0 48 [1] 1,549 [1]  
Repayments of long-term debt (671) (3,683) [1] (2,718) [1]  
Repayments of lease liabilities (282) (253) [1] (280) [1]  
Net change in short-term debt and other financial instruments [11] 59 751 [1] 216 [1]  
Acquisitions of treasury shares (302) (593) [1] (497) [1]  
Cash flows from (used in) financing activities, continuing operations (5,751) (8,048) [1] (5,807) [1]  
Net cash provided by/(used in) continuing financing activities (5,763) (8,052) [1] (5,821) [1]  
Cash flows from (used in) financing activities, discontinued operations (12) (4) [1] (14) [1]  
Impact of exchange rates on cash and cash equivalents (13) (32) [1] 8 [1]  
Effect of Reclassification of Discontinued Operation (167) 0 [1] 0 [1]  
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes (1,269) (4,026) [1] 2,638 [1]  
Cash and cash equivalents, beginning of period [1] 8,710 12,736 10,098  
Cash and cash equivalents at end of period 7,441 8,710 [1] 12,736 [1]  
Cash and cash equivalents, discontinued operations € 167 € 0 [1] € 0 [1] € 0
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).
[2] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[3] Includes non-current financial assets.
[4] This line item includes contributions paid to pension funds (see Note D.19.1.).
[5] This line item mainly comprises unrealized foreign exchange gains and losses arising on the remeasurement of monetary items in non-functional
currencies and on instruments used to hedge such items.
[6] Including:
2024
2023
2022
•Income tax paid
(3,291)
(2,623)
(2,452)
•Interest paid
(587)
(559)
(380)
•Interest received
447
547
173
•Dividends received from non-consolidated entities
52
17
1
[7] This line item includes payments made in respect of contingent consideration identified and recognized as a liability in business combinations. For 2024,
it includes the net cash outflow relating to the acquisition of Inhibrx, Inc. (see Note D.1..1). For 2023, it includes the net cash outflow on the acquisitions of
Provention Bio (see Note D.1.). For 2022, it includes the net cash outflow on the acquisition of Amunix (see Note D.1.)
[8] For 2024, this line item includes the sale of the Enjaymo global rights to Recordati for pre-tax proceeds of €768 million. For 2023 and 2022, this line item
mainly comprises disposals of assets and activities related to portfolio streamlining, and disposals of equity and debt instruments.
[9] For 2022, this line item includes the net cash inflows (before taxes) of €101 million on the divestment of EUROAPI (see Note D.1.).
[10] For 2023, this line item includes the net cash outflow on the acquisition of QRIB (see Note D.1.)
[11] For 2024, this line item mainly includes a US commercial paper program for €262 million. For 2024, 2023 and 2022, it also includes realized foreign
exchange differences on (i) cash and cash equivalents in non-functional currencies (primarily the US dollar) and (ii) derivative instruments used to
manage such cash and cash equivalents.